The world is currently experiencing a huge challenge which has affected all the industries and markets. Few markets have experienced a high growth in their demand while others have faced a downfall. The extent of growth or drop in the market statistics of different industries by COVID 19 plays an important role in how the future of businesses will shape up in the near future. We at Value Market Research provide you with an impact analysis of COVID 19 on this market with its latest update in the purchased version of the report.
Global Benign Prostatic Hyperplasia (BPH) And Prostate Treatment Market Report By Product (Alpha Blockers, 5-Alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitors And Others), Therapy (Monodrug Therapy And Combination Therapy) And By Regions - Industry Trends, Size, Share, Growth, Estimation And Forecast, 2021-2028
ID:VMR11210343
July 2021
Report Formats: Electronic (PDF), MS EXCEL
Global Benign Prostatic Hyperplasia (BPH) and Prostate Treatment Market Overview
Benign prostatic hyperplasia (BPH) is the medical condition typically observed in old-aged men characterized by enlargement of the prostate gland resulting in squeezing of the urethra. BPH can cause problems in the urinary bladder, kidney, and urinary tract. It is often treated with prescribed doses of alpha-blockers, 5-alpha reductase, or a combination of other drugs. For severe conditions, minimally invasive or laser therapies are also performed. The number of men seeking treatment for benign prostatic hyperplasia (BPH) is expected to rise in the coming years due to the growing aging male population and the increasing prevalence of obesity, cardiovascular diseases, and erectile dysfunction. BPH is a common condition in aging men and the most common cause of lower urinary tract symptoms. The prevalence of BPH rises after 40 years, with a prevalence of 8% to 60% at age 90 years. As per United Nations, the number of older persons is growing faster than the younger age groups. The global population aged over 80 years is projected to triple, increasing from 137 million in 2017 to 425 million in 2050. Obesity affects the geriatric population in parallel to that of the general population. The prevalence of obesity in the older population has been rising and now poses a major global threat in developed and developing countries. All of these will contribute to the growing prevalence of BPH, thus therapeutics.
The rise in awareness regarding urological diseases contributes to the growth of the benign prostatic hyperplasia treatment market. The growing preference for advanced treatment such as transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), transurethral microwave therapy (TUMT), and other minimally invasive techniques are also projected to foster the market growth during the timespan. Even if BPH is treated with drugs and surgeries, it does come with some side effects. Common side effects include dizziness, orthostatic hypotension, retrograde ejaculation, and rhinitis. Surgeries' side effects include pain, problems urinating, and other infections. This may hinder the market growth.
The global benign prostatic hyperplasia treatment market is highly fragmented. Abbott Laboratories, Allergan plc, Astellas Pharma, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Boehringer Ingelheim Pharma GmbH & Co. KG, Merck & Co., Inc., Pfizer, Inc., Sanofi, and Teva Pharmaceutical Industries Limited are key players associated with the market. Key companies are adopting merger & acquisition strategies and joint ventures to gain a more significant share in the overall market. Several companies are spending in R&D for the exploration of better treatment.
 and Prostate Treatment Market Report.jpg)
In this research report, the global Benign Prostatic Hyperplasia (BPH) and Prostate Treatment market is segmented by therapy and region.
Analysis, By Type:
By type, the global benign prostatic hyperplasia therapeutics market is segmented into drugs and surgeries. The drug segment occupies a major share in 2021. Drugs alone are known to be more effective. Drug therapy is growing due to its high effectiveness, superior symptomatic benefit, and significant reduction in adverse events.
Analysis, By Surgical Treatment:
Among surgical treatments, Transurethral Resection of the Prostate holds the maximum share for the year 2021.
Analysis, By Drug Treatment:
Among drugs, the alpha-blocker segment acquired a major share in the market and is expected to stay dominant throughout the forecast period, owing to high preference, superior therapeutic action, and availability of many alpha-blocker drugs. Alpha-blockers work by relaxing the prostate and bladder neck muscle and allows urine to flow more easily. The surgeries segment is also projected to grow significantly due to the growing severity of the condition and failure of drug treatment.
Analysis, By End User:
By end user, the market is segmented into home-healthcare settings, hospitals, and clinics. Home healthcare is the largest shareholder on the basis of revenue for the year 2021.
Analysis, By Region
Geographically, the global benign prostatic hyperplasia treatment market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is a dominant region in the global market, while the Asia-Pacific region is anticipated to grow faster during the forecast period. North America is expected to grow with the rising prevalence of benign prostatic hyperplasia, greater access to treatment. Also, the region is home to many market players and is blessed with skilled expertise. Asia Pacific growth is driven by factors including a high male population base, increased disposable income, and enhanced patient awareness about benign prostatic hyperplasia.
Market Segmentation covered in the Report:
By Type
By Surgical Treatment
By Drug Treatment
By End User
By Region
Benign prostatic hyperplasia (BPH) is the medical condition typically observed in old-aged men characterized by enlargement of the prostate gland resulting in squeezing of the urethra. BPH can cause problems in the urinary bladder, kidney, and urinary tract. It is often treated with prescribed doses of alpha-blockers, 5-alpha reductase, or a combination of other drugs. For severe conditions, minimally invasive or laser therapies are also performed. The number of men seeking treatment for benign prostatic hyperplasia (BPH) is expected to rise in the coming years due to the growing aging male population and the increasing prevalence of obesity, cardiovascular diseases, and erectile dysfunction. BPH is a common condition in aging men and the most common cause of lower urinary tract symptoms. The prevalence of BPH rises after 40 years, with a prevalence of 8% to 60% at age 90 years. As per United Nations, the number of older persons is growing faster than the younger age groups. The global population aged over 80 years is projected to triple, increasing from 137 million in 2017 to 425 million in 2050. Obesity affects the geriatric population in parallel to that of the general population. The prevalence of obesity in the older population has been rising and now poses a major global threat in developed and developing countries. All of these will contribute to the growing prevalence of BPH, thus therapeutics.
The global demand for benign prostatic hyperplasia (BPH) and prostate treatment market was valued at 10,584.19 USD MN in 2021 and is expected to generate revenue of 15,791.78 USD MN in 2028, growing at a CAGR of 5.62% between 2022 and 2028.
The rise in awareness regarding urological diseases contributes to the growth of the benign prostatic hyperplasia treatment market. The growing preference for advanced treatment such as transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), transurethral microwave therapy (TUMT), and other minimally invasive techniques are also projected to foster the market growth during the timespan. Even if BPH is treated with drugs and surgeries, it does come with some side effects. Common side effects include dizziness, orthostatic hypotension, retrograde ejaculation, and rhinitis. Surgeries' side effects include pain, problems urinating, and other infections. This may hinder the market growth.
The global benign prostatic hyperplasia treatment market is highly fragmented. Abbott Laboratories, Allergan plc, Astellas Pharma, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Boehringer Ingelheim Pharma GmbH & Co. KG, Merck & Co., Inc., Pfizer, Inc., Sanofi, and Teva Pharmaceutical Industries Limited are key players associated with the market. Key companies are adopting merger & acquisition strategies and joint ventures to gain a more significant share in the overall market. Several companies are spending in R&D for the exploration of better treatment.
In this research report, the global Benign Prostatic Hyperplasia (BPH) and Prostate Treatment market is segmented by therapy and region.
Analysis, By Type:
By type, the global benign prostatic hyperplasia therapeutics market is segmented into drugs and surgeries. The drug segment occupies a major share in 2021. Drugs alone are known to be more effective. Drug therapy is growing due to its high effectiveness, superior symptomatic benefit, and significant reduction in adverse events.
Analysis, By Surgical Treatment:
Among surgical treatments, Transurethral Resection of the Prostate holds the maximum share for the year 2021.
Analysis, By Drug Treatment:
Among drugs, the alpha-blocker segment acquired a major share in the market and is expected to stay dominant throughout the forecast period, owing to high preference, superior therapeutic action, and availability of many alpha-blocker drugs. Alpha-blockers work by relaxing the prostate and bladder neck muscle and allows urine to flow more easily. The surgeries segment is also projected to grow significantly due to the growing severity of the condition and failure of drug treatment.
Analysis, By End User:
By end user, the market is segmented into home-healthcare settings, hospitals, and clinics. Home healthcare is the largest shareholder on the basis of revenue for the year 2021.
Analysis, By Region
Geographically, the global benign prostatic hyperplasia treatment market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is a dominant region in the global market, while the Asia-Pacific region is anticipated to grow faster during the forecast period. North America is expected to grow with the rising prevalence of benign prostatic hyperplasia, greater access to treatment. Also, the region is home to many market players and is blessed with skilled expertise. Asia Pacific growth is driven by factors including a high male population base, increased disposable income, and enhanced patient awareness about benign prostatic hyperplasia.
Market Segmentation covered in the Report:
By Type
- Surgical Treatment
- Drug Treatment
By Surgical Treatment
- Transurethral Resection of the Prostate
- Transurethral Microwave Thermotherapy
- Transurethral Needle Ablation of the Prostate
- Laser Therapy
- Others (Prostatic Stenting, UroLift Therapy and Rezûm Therapy)
By Drug Treatment
- Alpha Blockers
- 5-alpha Reductase Inhibitors
- Others
By End User
- Home Healthcare Settings
- Others (Hospitals & Clinics)
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . BENIGN PROSTATIC HYPERPLASIA (BPH) AND PROSTATE TREATMENT – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Type
3.7.2 Market Attractiveness Analysis By Surgical Treatment
3.7.3 Market Attractiveness Analysis By Drug Treatment
3.7.4 Market Attractiveness Analysis By End User
3.7.5 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
5.1. Impact Analysis of Covid-19 Outbreak
5.1.1. Direct Impact on Production
5.1.2. Supply Chain and Market Disruption
5.1.3. Financial Impact on Firms and Financial Markets
5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
5.3. Market: Pre V/S Post COVID-19
5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
5.5. COVID-19: Micro and Macro Factor Analysis
6 . GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) AND PROSTATE TREATMENT MARKET ANALYSIS BY TYPE
6.1 Overview by Type
6.2 Historical and Forecast Data
6.3 Analysis by Type
6.4 Surgical Treatment Historic and Forecast Sales by Regions
6.5 Drug Treatment Historic and Forecast Sales by Regions
7 . GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) AND PROSTATE TREATMENT MARKET ANALYSIS BY SURGICAL TREATMENT
7.1 Overview by Surgical Treatment
7.2 Historical and Forecast Data
7.3 Analysis by Surgical Treatment
7.4 Transurethral Resection Of The Prostate Historic and Forecast Sales by Regions
7.5 Transurethral Microwave Thermotherapy Historic and Forecast Sales by Regions
7.6 Transurethral Needle Ablation Of The Prostate Historic and Forecast Sales by Regions
7.7 Laser Therapy Historic and Forecast Sales by Regions
7.8 Others (Prostatic Stenting, UroLift Therapy And Rezûm Therapy) Historic and Forecast Sales by Regions
8 . GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) AND PROSTATE TREATMENT MARKET ANALYSIS BY DRUG TREATMENT
8.1 Overview by Drug Treatment
8.2 Historical and Forecast Data
8.3 Analysis by Drug Treatment
8.4 Alpha Blockers Historic and Forecast Sales by Regions
8.5 5-alpha Reductase Inhibitors Historic and Forecast Sales by Regions
8.6 Others Historic and Forecast Sales by Regions
9 . GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) AND PROSTATE TREATMENT MARKET ANALYSIS BY END USER
9.1 Overview by End User
9.2 Historical and Forecast Data
9.3 Analysis by End User
9.4 Home Healthcare Settings Historic and Forecast Sales by Regions
9.5 Others (Hospitals & Clinics) Historic and Forecast Sales by Regions
10 . GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) AND PROSTATE TREATMENT MARKET ANALYSIS BY GEOGRAPHY
10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
10.3.1. Overview, Historic and Forecast Sales Analysis
10.3.2. North America By Segment Sales Analysis
10.3.3. North America By Country Sales Analysis
10.3.4. United State Sales Analysis
10.3.5. Canada Sales Analysis
10.3.6. Mexico Sales Analysis
10.4. Europe Sales Analysis
10.4.1. Overview, Historic and Forecast Sales Analysis
10.4.2. Europe by Segment Sales Analysis
10.4.3. Europe by Country Sales Analysis
10.4.4. United Kingdom Sales Analysis
10.4.5. France Sales Analysis
10.4.6. Germany Sales Analysis
10.4.7. Italy Sales Analysis
10.4.8. Russia Sales Analysis
10.4.9. Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
10.5.1. Overview, Historic and Forecast Sales Analysis
10.5.2. Asia Pacific by Segment Sales Analysis
10.5.3. Asia Pacific by Country Sales Analysis
10.5.4. China Sales Analysis
10.5.5. India Sales Analysis
10.5.6. Japan Sales Analysis
10.5.7. South Korea Sales Analysis
10.5.8. Australia Sales Analysis
10.5.9. Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
10.6.1. Overview, Historic and Forecast Sales Analysis
10.6.2. Latin America by Segment Sales Analysis
10.6.3. Latin America by Country Sales Analysis
10.6.4. Brazil Sales Analysis
10.6.5. Argentina Sales Analysis
10.6.6. Peru Sales Analysis
10.6.7. Chile Sales Analysis
10.6.8. Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
10.7.1. Overview, Historic and Forecast Sales Analysis
10.7.2. Middle East & Africa by Segment Sales Analysis
10.7.3. Middle East & Africa by Country Sales Analysis
10.7.4. Saudi Arabia Sales Analysis
10.7.5. UAE Sales Analysis
10.7.6. Israel Sales Analysis
10.7.7. South Africa Sales Analysis
10.7.8. Rest Of Middle East And Africa Sales Analysis
11 . COMPETITIVE LANDSCAPE OF THE BENIGN PROSTATIC HYPERPLASIA (BPH) AND PROSTATE TREATMENT COMPANIES
11.1. Benign Prostatic Hyperplasia (Bph) And Prostate Treatment Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments
12 . COMPANY PROFILES OF BENIGN PROSTATIC HYPERPLASIA (BPH) AND PROSTATE TREATMENT INDUSTRY
12.1. Top Company Share Analysis
12.2. Market Concentration Rate
12.3. Abbott Laboratories
12.3.1. Company Overview
12.3.2. Company Revenue
12.3.3. Products
12.3.4. Recent Developments
12.4. Allergan plc
12.4.1. Company Overview
12.4.2. Company Revenue
12.4.3. Products
12.4.4. Recent Developments
12.5. Astellas Pharma Inc.
12.5.1. Company Overview
12.5.2. Company Revenue
12.5.3. Products
12.5.4. Recent Developments
12.6. Eli Lilly and Company
12.6.1. Company Overview
12.6.2. Company Revenue
12.6.3. Products
12.6.4. Recent Developments
12.7. GlaxoSmithKline plc
12.7.1. Company Overview
12.7.2. Company Revenue
12.7.3. Products
12.7.4. Recent Developments
12.8. Boehringer Ingelheim Pharma GmbH & Co. KG
12.8.1. Company Overview
12.8.2. Company Revenue
12.8.3. Products
12.8.4. Recent Developments
12.9. Merck & Co. Inc.
12.9.1. Company Overview
12.9.2. Company Revenue
12.9.3. Products
12.9.4. Recent Developments
12.10. Pfizer Inc.
12.10.1. Company Overview
12.10.2. Company Revenue
12.10.3. Products
12.10.4. Recent Developments
12.11. Sanofi
12.11.1. Company Overview
12.11.2. Company Revenue
12.11.3. Products
12.11.4. Recent Developments
12.12. Teva Pharmaceutical Industries Limited
12.12.1. Company Overview
12.12.2. Company Revenue
12.12.3. Products
12.12.4. Recent Developments
*Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
LIST OF TABLES
- Market Snapshot
- Drivers : Impact Analysis
- Restraints : Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- List of Potential Buyers
- COVID-19 Impact Analysis by Production, Import, Export and Demand
- Pre V/S Post COVID-19
- Estimated Impact Of The Coronavirus (Covid-19) Epidemic
- COVID-19: Micro and Macro Factor Analysis
- Analysis by Type (USD MN)
- Surgical Treatment Market Sales by Geography (USD MN)
- Drug Treatment Market Sales by Geography (USD MN)
- Analysis Market by Surgical Treatment (USD MN)
- Transurethral Resection Of The Prostate Market Sales by Geography (USD MN)
- Transurethral Microwave Thermotherapy Market Sales by Geography (USD MN)
- Transurethral Needle Ablation Of The Prostate Market Sales by Geography (USD MN)
- Laser Therapy Market Sales by Geography (USD MN)
- Others (Prostatic Stenting, UroLift Therapy And Rezûm Therapy) Market Sales by Geography (USD MN)
- Analysis by Drug Treatment (USD MN)
- Alpha Blockers Market Sales by Geography (USD MN)
- 5-alpha Reductase Inhibitors Market Sales by Geography (USD MN)
- Others Market Sales by Geography (USD MN)
- Analysis by End User (USD MN)
- Home Healthcare Settings Market Sales by Geography (USD MN)
- Others (Hospitals & Clinics) Market Sales by Geography (USD MN)
- Global Benign Prostatic Hyperplasia (Bph) And Prostate Treatment Market Sales by Geography (USD MN)
- North America Market Analysis (USD MN)
- United State Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate by Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisition
LIST OF FIGURES
- Research Scope of Benign Prostatic Hyperplasia (Bph) And Prostate Treatment Report
- Market Research Process
- Market Research Methodology
- Global Benign Prostatic Hyperplasia (Bph) And Prostate Treatment Market Size, by Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis by Type
- Market Attractiveness Analysis by Surgical Treatment
- Market Attractiveness Analysis by Drug Treatment
- Market Attractiveness Analysis by End User
- Market Attractiveness Analysis by Region
- Value Chain Analysis
- Global Market Analysis by Type (USD MN)
- Surgical Treatment Market Sales by Geography (USD MN)
- Drug Treatment Market Sales by Geography (USD MN)
- Global Market Analysis by Surgical Treatment (USD MN)
- Transurethral Resection Of The Prostate Market Sales by Geography (USD MN)
- Transurethral Microwave Thermotherapy Market Sales by Geography (USD MN)
- Transurethral Needle Ablation Of The Prostate Market Sales by Geography (USD MN)
- Laser Therapy Market Sales by Geography (USD MN)
- Others (Prostatic Stenting, UroLift Therapy And Rezûm Therapy) Market Sales by Geography (USD MN)
- Global Market Analysis by Drug Treatment (USD MN)
- Alpha Blockers Market Sales by Geography (USD MN)
- 5-alpha Reductase Inhibitors Market Sales by Geography (USD MN)
- Others Market Sales by Geography (USD MN)
- Global Market Analysis by End User (USD MN)
- Home Healthcare Settings Market Sales by Geography (USD MN)
- Others (Hospitals & Clinics) Market Sales by Geography (USD MN)
- Global Market by Revenue
- North America Market by Revenue
- Europe Market by Revenue
- Asia Pacific Market by Revenue
- Latin America Market by Revenue
- Middle East & Africa Market by Revenue
- Recent Development in Industry
- Top Company Share Analysis
* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
Related Categories
Healthcare
Buy Chapters or Sections
Avail customized purchase options to meet your exact research needs:
- Buy sections of this report
- Buy country level reports
- Request for historical data
- Request discounts available for Start-Ups & Universities
Objectives of Study
- Define and measure the global market
- Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
- Analyze and identify major market trends along with the factors driving or inhibiting the market growth
- Study the company profiles of the major market players with their market share
- Analyze competitive developments